- Home
- BL vs CRSP Comparison
BL vs CRSP Comparison
Compare BL & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BL
- CRSP
- Stock Information
- Founded
- BL 2001
- CRSP 2013
- Country
- BL United States
- CRSP Switzerland
- Employees
- BL N/A
- CRSP N/A
- Industry
- BL Computer Software: Prepackaged Software
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BL Technology
- CRSP Health Care
- Exchange
- BL Nasdaq
- CRSP Nasdaq
- Market Cap
- BL 3.8B
- CRSP 3.4B
- IPO Year
- BL 2016
- CRSP 2016
- Fundamental
- Price
- BL $59.65
- CRSP $40.53
- Analyst Decision
- BL Hold
- CRSP Buy
- Analyst Count
- BL 12
- CRSP 19
- Target Price
- BL $66.00
- CRSP $77.13
- AVG Volume (30 Days)
- BL 553.2K
- CRSP 1.8M
- Earning Date
- BL 02-11-2025
- CRSP 02-19-2025
- Dividend Yield
- BL N/A
- CRSP N/A
- EPS Growth
- BL 45.65
- CRSP N/A
- EPS
- BL 0.98
- CRSP N/A
- Revenue
- BL $639,606,000.00
- CRSP $202,829,000.00
- Revenue This Year
- BL $13.81
- CRSP N/A
- Revenue Next Year
- BL $9.05
- CRSP $724.16
- P/E Ratio
- BL $60.85
- CRSP N/A
- Revenue Growth
- BL 11.39
- CRSP 19.31
- 52 Week Low
- BL $43.37
- CRSP $36.52
- 52 Week High
- BL $69.31
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- BL 48.32
- CRSP 44.09
- Support Level
- BL $55.00
- CRSP $36.52
- Resistance Level
- BL $61.66
- CRSP $40.99
- Average True Range (ATR)
- BL 1.57
- CRSP 1.78
- MACD
- BL -0.06
- CRSP 0.23
- Stochastic Oscillator
- BL 63.79
- CRSP 51.68
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.